Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients

After the landmark approval of T-VEC, oncolytic viruses are finding their way to the clinics. However, response rates have still room for improvement, and unfortunately there are currently no available markers to predict responses for oncolytic immunotherapy. Interleukin 8 (IL-8) production is upreg...

Descripción completa

Detalles Bibliográficos
Autores principales: Taipale, Kristian, Tähtinen, Siri, Havunen, Riikka, Koski, Anniina, Liikanen, Ilkka, Pakarinen, Päivi, Koivisto-Korander, Riitta, Kankainen, Matti, Joensuu, Timo, Kanerva, Anna, Hemminki, Akseli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814215/
https://www.ncbi.nlm.nih.gov/pubmed/29464075
http://dx.doi.org/10.18632/oncotarget.23967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814215/
https://www.ncbi.nlm.nih.gov/pubmed/29464075
http://dx.doi.org/10.18632/oncotarget.23967

Ejemplares similares